> Detailanzeige

Gaglani, Manjusha; Kim, Sara S; Naleway, Allison L; Levine, Min Z; Edwards, Laura; Murthy, Kempapura; Dunnigan, Kayan; Zunie, Tnelda; Groom, Holly; Ball, Sarah; Jeddy, Zuha; Hunt, Danielle; Wesley, Meredith G; Sambhara, Suryaprakash; Gangappa, Shivaprakash; Grant, Lauren; Cao, Weiping; Gross, F Liaini; Mishina, Margarita; Fry, Alicia M; Thompson, Mark G; Dawood, Fatimah S; Flannery, Brendan

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial
  • Beteiligte: Gaglani, Manjusha; Kim, Sara S; Naleway, Allison L; Levine, Min Z; Edwards, Laura; Murthy, Kempapura; Dunnigan, Kayan; Zunie, Tnelda; Groom, Holly; Ball, Sarah; Jeddy, Zuha; Hunt, Danielle; Wesley, Meredith G; Sambhara, Suryaprakash; Gangappa, Shivaprakash; Grant, Lauren; Cao, Weiping; Gross, F Liaini; Mishina, Margarita; Fry, Alicia M; Thompson, Mark G; Dawood, Fatimah S; Flannery, Brendan
  • Erschienen: Oxford University Press (OUP), 2023
  • Erschienen in: Clinical Infectious Diseases
  • Sprache: Englisch
  • DOI: 10.1093/cid/ciac683
  • ISSN: 1058-4838; 1537-6591
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Antibody responses to non–egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin [HA]/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>In a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personnel (HCP) aged 18–64 years over 2 consecutive seasons, HCP who received recombinant-HA influenza vaccine (RIV) or cell culture–based inactivated influenza vaccine (ccIIV) during the first season (year 1) were re-randomized the second season of 2019–2020 (year 2 [Y2]) to receive ccIIV or RIV, resulting in 4 ccIIV/RIV combinations. In Y2, hemagglutination inhibition antibody titers against reference cell–grown vaccine viruses were compared in each ccIIV/RIV group with titers among HCP randomized both seasons to receive egg-based, standard-dose inactivated influenza vaccine (IIV) using geometric mean titer (GMT) ratios of Y2 post-vaccination titers.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Y2 data from 414 HCP were analyzed per protocol. Compared with 60 IIV/IIV recipients, 74 RIV/RIV and 106 ccIIV/RIV recipients showed significantly elevated GMT ratios (Bonferroni corrected P &amp;lt; .007) against all components except A(H3N2). Post-vaccination GMT ratios for ccIIV/ccIIV and RIV/ccIIV were not significantly elevated compared with IIV/IIV except for RIV/ccIIV against A(H1N1)pdm09.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>In adult HCP, receipt of RIV in 2 consecutive seasons or the second season was more immunogenic than consecutive egg-based IIV for 3 of the 4 components of quadrivalent vaccine. Immunogenicity of ccIIV/ccIIV was similar to that of IIV/IIV. Differences in HA antigen content may play a role in immunogenicity of influenza vaccination in consecutive seasons.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trials Registration</jats:title> <jats:p>NCT03722589.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang